New avenues for therapeutic discovery against West Nile virus

References

• Barzon L. Ongoing and emerging arbovirus threats in Europe. J Clin Virol. 2018;107:38–47.
   PubMed Web of Science ®Google Scholar
• Ulbert S, Magnusson SE. Technologies for the development of West Nile virus vaccines. Future Microbiol. 2014;9(10):1221–1232.
   PubMed Web of Science ®Google Scholar
• Ulbert S. West Nile virus vaccines - current situation and future directions. Hum Vaccin Immunother. 2019 Jul;10:1–6.
   Google Scholar
• Biedenbender R, Bevilacqua J, Gregg AM, et al. Phase II, randomized, double-blind, placebo-controlled, multicenter study to investigate the immunogenicity and safety of a West Nile virus vaccine in healthy adults. J Infect Dis. 2011;203(1):75–84.
   PubMed Web of Science ®Google Scholar
• Dayan GH, Bevilacqua J, Coleman D, et al. Phase II, dose ranging study of the safety and immunogenicity of single dose West Nile vaccine in healthy adults ≥ 50 years of age. Vaccine. 2012;30(47):6564–6656.
   PubMed Web of Science ®Google Scholar
• Smith HL, Monath TP, Pazoles P, et al. Development of antigen-specific memory CD8+ T cells following live-attenuated chimeric West Nile virus vaccination. J Infect Dis. 2011;203(4):513–522.
   PubMed Web of Science ®Google Scholar
• Durbin AP, Wright PF, Cox A, et al. The live attenuated chimeric vaccine rWN/DEN4Δ30 is well-tolerated and immunogenic in healthy flavivirus-naïve adult volunteers. Vaccine. 2013;31(48):5772–5777.
   PubMed Web of Science ®Google Scholar
• Ledgerwood JE, Pierson TC, Hubka SA, et al. A West Nile virus DNA vaccine utilizing a modified promoter induces neutralizing antibody in younger and older healthy adults in a phase I clinical trial. J Infect Dis. 2011;203(10):1396–1404.
   PubMed Web of Science ®Google Scholar
• Woods CW, Sanchez AM, Swamy GK, et al. An observer blinded, randomized, placebo-controlled, phase I dose escalation trial to evaluate the safety and immunogenicity of an inactivated West Nile virus vaccine, hydrovax-001, in healthy adults. Vaccine. 2019;37(30):4222–4230.
   PubMed Web of Science ®Google Scholar
• Lieberman MM, Nerurkar VR, Luo H, et al. Immunogenicity and protective efficacy of a recombinant subunit West Nile virus vaccine in rhesus monkeys. Clin Vaccine Immunol. 2009;16(9):1332–1337.
   PubMedGoogle Scholar
• Verstrepen BE, Oostermeijer H, Fagrouch Z, et al. Vaccine-induced protection of rhesus macaques against plasma viremia after intradermal infection with a European lineage 1 strain of West Nile virus. PLoS One. 2014;9(11):e112568.
   PubMed Web of Science ®Google Scholar
• Magnusson SE, Karlsson KH, Reimer JM, et al. Matrix-M™ adjuvanted envelope protein vaccine protects against lethal lineage 1 and 2 West Nile virus infection in mice. Vaccine. 2014;32(7):800–808.
   PubMed Web of Science ®Google Scholar
• De Filette M, Soehle S, Ulbert S, et al. Vaccination of mice using the West Nile virus E-protein in a DNA prime-protein boost strategy stimulates cell-mediated immunity and protects mice against a lethal challenge. PLoS One. 2014;9(2):e87837.
   PubMed Web of Science ®Google Scholar
• Van Hoeven N, Joshi SW, Nana GI, et al. A novel synthetic TLR-4 agonist adjuvant increases the protective response to a clinical-stage West Nile virus vaccine antigen in multiple formulations. PLoS One. 2016;11(2):e0149610.
   PubMed Web of Science ®Google Scholar
• Boldescu V, Behnam MAM, Vasilakis N. et al. Broad-spectrum agents for flaviviral infections: dengue, Zika and beyond. Nat Rev Drug Discov. 2017;16(8):565–586.
   PubMed Web of Science ®Google Scholar
• Barzon L, Palù G. Recent developments in vaccines and biological therapies against Japanese encephalitis virus. Expert Opin Biol Ther. 2018;18(8):851–864.
   PubMed Web of Science ®Google Scholar
• Sinigaglia A, Riccetti S, Trevisan M, et al. In silico approaches to Zika virus drug discovery. Expert Opin Drug Discov. 2018;13(9):825–835.
   PubMed Web of Science ®Google Scholar
• Kalil AC, Devetten MP, Singh S, et al. Use of interferon-alpha in patients with West Nile encephalitis: report of 2 cases. Clin Infect Dis. 2005;40(5):764–766.
   PubMed Web of Science ®Google Scholar
• Morrey JD, Day CW, Julander JG, et al. Effect of interferon-alpha and interferon-inducers on West Nile virus in mouse and hamster animal models. Antivir Chem Chemother. 2004;15(2):101–109.
   PubMedGoogle Scholar
• Chowers MY, Lang R, Nassar F, et al. Clinical characteristics of the West Nile fever outbreak, Israel, 2000. Emerg Infect Dis. 2001;7(4):675–678.
   PubMed Web of Science ®Google Scholar
• Hrnicek MJ, Mailliard ME. Acute West Nile virus in two patients receiving interferon and ribavirin for chronic hepatitis C. Am J Gastroenterol. 2004;99(5):957.
   PubMed Web of Science ®Google Scholar
• Barzon L, Trevisan M, Sinigaglia A, et al. Zika virus: from pathogenesis to disease control. FEMS Microbiol Lett. 2016;363(18):fnw202.
   PubMed Web of Science ®Google Scholar
• Wilder-Smith A, Ooi EE, Horstick O, et al. Dengue. Lancet. 2019;393(10169):350–363.
   PubMed Web of Science ®Google Scholar
• McDonald E, Martin SW, Landry K, et al. West Nile virus and other domestic nationally notifiable arboviral diseases - United States, 2018. MMWR Morb Mortal Wkly Rep. 2019;68(31):673–678.
   PubMed Web of Science ®Google Scholar
• Haussig JM, Young JJ, Gossner CM, et al. Early start of the West Nile fever transmission season 2018 in Europe. Euro Surveill. 2018;23:32.
   Google Scholar
• Suthar MS, Diamond MS, Jr GM. West Nile virus infection and immunity. Nat Rev Microbiol. 2013;11(2):115–128.
   PubMed Web of Science ®Google Scholar
• Perera-Lecoin M, Meertens L, Carnec X, et al. Flavivirus entry receptors: an update. Viruses. 2013;6(1):69–88.
   PubMed Web of Science ®Google Scholar
• Neufeldt CJ, Cortese M, Acosta EG, et al. Rewiring cellular networks by members of the Flaviviridae family. Nat Rev Microbiol. 2018;16(3):125–142.
   PubMed Web of Science ®Google Scholar
• Bollati M1, Alvarez K, Assenberg R, et al. Structure and functionality in flavivirus NS-proteins: perspectives for drug design. Antiviral Res. 2010;87:125–148.
   PubMed Web of Science ®Google Scholar
• Nall TA, Chappell KJ, Stoermer MJ, et al. Enzymatic characterization and homology model of a catalytically active recombinant West Nile virus NS3 protease. J Biol Chem. 2004;279(47):48535–48542.
   PubMed Web of Science ®Google Scholar
• Chappell KJ, Stoermer MJ, Fairlie DP, et al. Insights to substrate binding and processing by West Nile virus NS3 protease through combined modeling, protease mutagenesis, and kinetic studies. J Biol Chem. 2006;281:38448–38458.
   PubMed Web of Science ®Google Scholar
• Malet H, Massé N, Selisko B, et al. The flavivirus polymerase as a target for drug discovery. Antiviral Res. 2008;80(1):23–35.
   PubMed Web of Science ®Google Scholar
• Nybakken GE, Nelson CA, Chen BR, et al. Crystal structure of the West Nile virus envelope glycoprotein. J Virol. 2006;80:11467–11474.
   PubMed Web of Science ®Google Scholar
• Modis Y, Ogata S, Clements D, et al. Structure of the dengue virus envelope protein after membrane fusion. Nature. 2004;427:313–319.
   PubMed Web of Science ®Google Scholar
• Oliveira ERA, Mohana-Borges R2, de Alencastro RB, et al. The flavivirus capsid protein: structure, function and perspectives towards drug design. Virus Res. 2017;227:115–123.
   PubMed Web of Science ®Google Scholar
• Li M, Johnson JR, Truong B, et al. Identification of antiviral roles for the exon-junction complex and nonsense-mediated decay in flaviviral infection. Nat Microbiol. 2019;4(6):985–995.
   PubMed Web of Science ®Google Scholar
• Gutsche I, Coulibaly F, Voss JE, et al. Secreted dengue virus nonstructural protein NS1 is an atypical barrel-shaped high-density lipoprotein. Proc Natl Acad Sci U S A. 2011;108(19):8003–8008.
   PubMed Web of Science ®Google Scholar
• Westaway EG, Goodman MR. Variation in distribution of the three flavivirus-specified glycoproteins detected by immunofluorescence in infected Vero cells. Arch Virol. 1987;94(3–4):215–228.
   PubMed Web of Science ®Google Scholar
• Westaway EG, Mackenzie JM, Kenney MT, et al. Ultrastructure of Kunjin virus-infected cells: colocalization of NS1 and NS3 with double-stranded RNA, and of NS2B with NS3, in virus-induced membrane structures. J Virol. 1997;71(9):6650–6661.
   PubMed Web of Science ®Google Scholar
• Chung KM, Liszewski MK, Nybakken G, et al. West Nile virus nonstructural protein NS1 inhibits complement activation by binding the regulatory protein factor H. Proc Natl Acad Sci U S A. 2006;103(50):19111–19116.
   PubMed Web of Science ®Google Scholar
• Patel S, Sinigaglia A, Barzon L, et al. Role of NS1 and TLR3 in pathogenesis and immunity of WNV. Viruses. 2019;11(7):E603.
   PubMed Web of Science ®Google Scholar
• Whiteman MC, Wicker JA, Kinney RM, et al. Multiple amino acid changes at the first glycosylation motif in NS1 protein of West Nile virus are necessary for complete attenuation for mouse neuroinvasiveness. Vaccine. 2011;29(52):9702–9710.
   PubMed Web of Science ®Google Scholar
• Wilson JR, de Sessions PF, Leon MA, et al. West Nile virus nonstructural protein 1 inhibits TLR3 signal transduction. J Virol. 2008;82(17):8262–8271.
   PubMed Web of Science ®Google Scholar
• Zhang HL, Ye HQ, Liu SQ, et al. West Nile virus NS1 Antagonizes Interferon Beta Production by Targeting RIG-I and MDA5. J Virol. 2017;91(18):e02396–16.
   PubMed Web of Science ®Google Scholar
• Youn S, Li T, McCune BT, et al. Evidence for a genetic and physical interaction between nonstructural proteins NS1 and NS4B that modulates replication of West Nile virus. J Virol. 2012;86(13):7360–7371.
   PubMed Web of Science ®Google Scholar
• Luo D, Xu T, Watson RP, et al. Insights into RNA unwinding and ATP hydrolysis by the flavivirus NS3 protein. Embo J. 2008;27(23):3209–3219.
   PubMed Web of Science ®Google Scholar
• Sweeney NL, Hanson AM, Mukherjee S, et al. Benzothiazole and pyrrolone flavivirus inhibitors targeting the viral helicase. ACS Infect Dis. 2015;1(3):140–148.
   PubMed Web of Science ®Google Scholar
• Chung KY, Dong H, Chao AT, et al. Higher catalytic efficiency of N-7-methylation is responsible for processive N-7 and 2ʹ-O methyltransferase activity in dengue virus. Virology. 2010;402(1):52–60.
   PubMed Web of Science ®Google Scholar
• Dong H, Liu L, Zou G, et al. Structural and functional analyses of a conserved hydrophobic pocket of flavivirus methyltransferase. J Biol Chem. 2010;285(42):32586–32595.
   PubMed Web of Science ®Google Scholar
• Vernekar SK, Qiu L, Zhang J, et al. 5ʹ-Silylated 3ʹ-1,2,3-triazolyl thymidine analogues as inhibitors of West Nile virus and dengue virus. J Med Chem. 2015;58(9):4016–4028.
   PubMed Web of Science ®Google Scholar
• Van Slyke GA, Ciota AT, Willsey GG, et al. Point mutations in the West Nile virus (Flaviviridae; Flavivirus) RNA-dependent RNA polymerase alter viral fitness in a host-dependent manner in vitro and in vivo. Virology. 2012;427(1):18–24.
   PubMed Web of Science ®Google Scholar
• Deardorff ER, Fitzpatrick KA, Jerzak GV, et al. West Nile virus experimental evolution in vivo and the trade-off hypothesis. PLoS Pathog. 2011;7(11):e1002335.
   PubMed Web of Science ®Google Scholar
• Gack MU, Diamond MS. Innate immune escape by dengue and West Nile viruses. Curr Opin Virol. 2016;20:119–128.
   PubMed Web of Science ®Google Scholar
• Hoenen A, Liu W, Kochs G, et al. West Nile virus-induced cytoplasmic membrane structures provide partial protection against the interferon-induced antiviral MxA protein. J Gen Virol. 2007;88(Pt 11):3013–3017.
   PubMedGoogle Scholar
• Szretter KJ, Daniels BP, Cho H, et al. 2ʹ-O methylation of the viral mRNA cap by West Nile virus evades ifit1-dependent and -independent mechanisms of host restriction in vivo. PLoS Pathog. 2012;8(5):e1002698.
   PubMed Web of Science ®Google Scholar
• Chen S, Wu Z, Wang M, et al. Innate immune evasion mediated by Flaviviridae non-structural proteins. Viruses. 2017;9(10):291.
   PubMed Web of Science ®Google Scholar
• Avirutnan P, Fuchs A, Hauhart RE, et al. Antagonism of the complement component C4 by flavivirus nonstructural protein NS1. J Exp Med. 2010;207(4):793–806.
   PubMed Web of Science ®Google Scholar
• Glasner DR, Puerta-Guardo H, Beatty PR, et al. The good, the bad, and the shocking: the multiple roles of dengue virus nonstructural protein 1 in protection and pathogenesis. Annu Rev Virol. 2018;5(1):227–253.
   PubMed Web of Science ®Google Scholar
• Wang C, Puerta-Guardo H, Biering SB, et al. Endocytosis of flavivirus NS1 is required for NS1-mediated endothelial hyperpermeability and is abolished by a single N-glycosylation site mutation. PLoS Pathog. 2019;15(7):e1007938.
   PubMed Web of Science ®Google Scholar
• Puerta-Guardo H, Glasner DR, Espinosa DA, et al. Flavivirus NS1 triggers tissue-specific vascular endothelial dysfunction reflecting disease tropism. Cell Rep. 2019;26(6):1598–1613.e8.
   PubMed Web of Science ®Google Scholar
• Liu WJ, Chen HB, Wang XJ, et al. Analysis of adaptive mutations in Kunjin virus replicon RNA reveals a novel role for the flavivirus nonstructural protein NS2A in inhibition of beta interferon promoter-driven transcription. J Virol. 2004;78(22):12225–12235.
   PubMed Web of Science ®Google Scholar
• Liu WJ, Wang XJ, Clark DC, et al. A single amino acid substitution in the West Nile virus nonstructural protein NS2A disables its ability to inhibit alpha/beta interferon induction and attenuates virus virulence in mice. J Virol. 2006;80(5):2396–2404.
   PubMed Web of Science ®Google Scholar
• Mackenzie JM, Khromykh AA, Parton RG. Cholesterol manipulation by West Nile virus perturbs the cellular immune response. Cell Host Microbe. 2007;2:229–239.
   PubMed Web of Science ®Google Scholar
• Laurent-Rolle M, Boer EF, Lubick KJ, et al. The NS5 protein of the virulent West Nile virus NY99 strain is a potent antagonist of type I interferon-mediated JAK-STAT signaling. J Virol. 2010;84(7):3503–3515.
   PubMed Web of Science ®Google Scholar
• Samuel GH, Adelman ZN, Myles KM. Antiviral immunity and virus-mediated antagonism in disease vector mosquitoes. Trends Microbiol. 2018;26(5):447–461.
   PubMed Web of Science ®Google Scholar
• Roby JA, Pijlman GP, Wilusz J, et al. Noncoding subgenomic flavivirus RNA: multiple functions in West Nile virus pathogenesis and modulation of host responses. Viruses. 2014;6(2):404–427.
   PubMed Web of Science ®Google Scholar
• Pijlman GP, Funk A, Kondratieva N, et al. A highly structured, nuclease-resistant, noncoding RNA produced by flaviviruses is required for pathogenicity. Cell Host Microbe. 2008;4(6):579–591.
   PubMed Web of Science ®Google Scholar
• Manokaran G, Finol E, Wang C, et al. Dengue subgenomic RNA binds TRIM25 to inhibit interferon expression for epidemiological fitness. Science. 2015;350(6257):217–221.
   PubMed Web of Science ®Google Scholar
• Schuessler A, Funk A, Lazear HM, et al. West Nile virus noncoding subgenomic RNA contributes to viral evasion of the type I interferon-mediated antiviral response. J Virol. 2012;86(10):5708–5718.
   PubMed Web of Science ®Google Scholar
• Martins AS, Carvalho FA, Faustino AF, et al. West Nile virus capsid protein interacts with biologically relevant host lipid systems. Front Cell Infect Microbiol. 2019;9:8.
   PubMed Web of Science ®Google Scholar
• Faustino AF, Guerra GM, Huber RG, et al. Understanding dengue virus capsid protein disordered N-Terminus and pep14–23-based inhibition. ACS Chem Biol. 2015;10(2):517–526.
   PubMed Web of Science ®Google Scholar
• Martins IC, Gomes-Neto F, Faustino AF, et al. The disordered N-terminal region of dengue virus capsid protein contains a lipid-droplet-binding motif. Biochem J. 2012;444(3):405–415.
   PubMedGoogle Scholar
• Byrd CM, Dai D, Grosenbach DW, et al. A novel inhibitor of dengue virus replication that targets the capsid protein. Antimicrob Agents Chemother. 2013;57(1):15–25.
   PubMed Web of Science ®Google Scholar
• Scaturro P, Trist IM, Paul D, et al. Characterization of the mode of action of a potent dengue virus capsid inhibitor. J Virol. 2014;88(19):11540–11555.
   PubMed Web of Science ®Google Scholar
• Kampmann T, Yennamalli R, Campbell P, et al. In silico screening of small molecule libraries using the dengue virus envelope E protein has identified compounds with antiviral activity against multiple flaviviruses. Antiviral Res. 2009;84(3):234–241.
   PubMed Web of Science ®Google Scholar
• de Wispelaere M, Lian W, Potisopon S, et al. Inhibition of flaviviruses by targeting a conserved pocket on the viral envelope protein. Cell Chem Biol. 2018;25(89):1006–1016.
   PubMedGoogle Scholar
• Vázquez-Calvo Á, Jiménez de Oya N, Martín-Acebes MA, et al. Antiviral properties of the natural polyphenols delphinidin and epigallocatechin gallate against the flaviviruses West Nile virus, Zika virus, and Dengue virus. Front Microbiol. 2017;8:1314.
   PubMed Web of Science ®Google Scholar
• Lee E, Pavy M, Young N, et al. Antiviral effect of the heparan sulfate mimetic, PI-88, against dengue and encephalitic flaviviruses. Antiviral Res. 2006;69(1):31–38.
   PubMed Web of Science ®Google Scholar
• Engle MJ, Diamond MS. Antibody prophylaxis and therapy against West Nile virus infection in wild-type and immunodeficient mice. J Virol. 2003;77(24):12941–12949.
   PubMed Web of Science ®Google Scholar
• Makhoul B, Braun E, Herskovitz M, et al. Hyperimmune gammaglobulin for the treatment of West Nile virus encephalitis. Isr Med Assoc J. 2009;11(3):151–153.
   PubMed Web of Science ®Google Scholar
• Morelli MC, Sambri V, Grazi GL, et al. Absence of neuroinvasive disease in a liver transplant recipient who acquired West Nile virus (WNV) infection from the organ donor and who received WNV antibodies prophylactically. Clin Infect Dis. 2010;51(4):e34–37.
   PubMed Web of Science ®Google Scholar
• Center for Disease Control and Prevention (CDC). West Nile virus disease therapeutics. Review of the literature for healthcare providers. Revised February; 2018 3 [cited 2019 Sept 8]. Available from: https://www.cdc.gov/westnile/resources/pdfs/WNV-therapeutics-summary-P.pdf
   Google Scholar
• Sun H, Chen Q, Lai H. Development of antibody therapeutics against flaviviruses. Int J Mol Sci. 2017;19(1):E54.
   PubMed Web of Science ®Google Scholar
• Gnann JW Jr, Agrawal A, Hart J, et al. Lack of efficacy of high-titered immunoglobulin in patients with West Nile virus central nervous system disease. Emerg Infect Dis. 2019;25(11):2064–2073.
   PubMed Web of Science ®Google Scholar
• Pierson TC, Diamond MS. Molecular mechanisms of antibody-mediated neutralisation of flavivirus infection. Expert Rev Mol Med. 2008;10:e12.
   PubMedGoogle Scholar
• Rey FA, Stiasny K, Vaney MC, et al. The bright and the dark side of human antibody responses to flaviviruses: lessons for vaccine design. EMBO Rep. 2018;19(2):206–224.
   PubMed Web of Science ®Google Scholar
• Sinigaglia A, Pacenti M, Martello T, et al. West Nile virus infection in individuals with pre-existing Usutu virus immunity, northern Italy, 2018. Euro Surveill. 2019;24(21):1900261.
   PubMedGoogle Scholar
• Pierson TC, Xu Q, Nelson S, et al. The stoichiometry of antibody-mediated neutralization and enhancement of West Nile virus infection. Cell Host Microbe. 2007;1(2):135–145.
   PubMed Web of Science ®Google Scholar
• Chabierski S, Makert GR, Kerzhner A, et al. Antibody responses in humans infected with newly emerging strains of West Nile virus in Europe. PLoS One. 2013;8(6):e66507.
   PubMed Web of Science ®Google Scholar
• Oliphant T, Engle M, Nybakken GE, et al. Development of a humanized monoclonal antibody with therapeutic potential against West Nile virus. Nat Med. 2005 May;11(5):522–530.
   PubMed Web of Science ®Google Scholar
• Morrey JD, Siddharthan V, Olsen AL, et al. Humanized monoclonal antibody against West Nile virus envelope protein administered after neuronal infection protects against lethal encephalitis in hamsters. J Infect Dis. 2006;194(9):1300–1308.
   PubMed Web of Science ®Google Scholar
• Smeraski CA, Siddharthan V, Morrey JD. Treatment of spatial memory impairment in hamsters infected with West Nile virus using a humanized monoclonal antibody MGAWN1. Antiviral Res. 2011;91(1):43–49.
   PubMed Web of Science ®Google Scholar
• Lai H, Engle M, Fuchs A, et al. Monoclonal antibody produced in plants efficiently treats West Nile virus infection in mice. Proc Natl Acad Sci U S A. 2010;107(6):2419–2424.
   PubMed Web of Science ®Google Scholar
• He J, Lai H, Engle M, et al. Generation and analysis of novel plant-derived antibody-based therapeutic molecules against West Nile virus. PLoS One. 2014;9(3):e93541.
   PubMed Web of Science ®Google Scholar
• Goo L, Debbink K, Kose N. et al. A protective human monoclonal antibody targeting the West Nile virus E protein preferentially recognizes mature virions. Nat Microbiol. 2019;4(1):71–77.
   PubMed Web of Science ®Google Scholar
• Beigel JH, Nordstrom JL, Pillemer SR, et al. Safety and pharmacokinetics of single intravenous dose of MGAWN1, a novel monoclonal antibody to West Nile virus. Antimicrob Agents Chemother. 2010;54(6):2431–2436.
   PubMed Web of Science ®Google Scholar
• Morrey JD, Siddharthan V, Olsen AL, et al. Defining limits of treatment with humanized neutralizing monoclonal antibody for West Nile virus neurological infection in a hamster model. Antimicrob Agents Chemother. 2007;51(7):2396–2402.
   PubMed Web of Science ®Google Scholar
• [cited 2019 Sep 5]. Available from: http://clinicaltrials.gov/ct2/show/NCT00927953?term=west±nile&rank=1
   Google Scholar
• Ezgimen M, Lai H, Mueller NH, et al. Characterization of the 8-hydroxyquinoline scaffold for inhibitors of West Nile virus serine protease. Antivir Res. 2012;94:18e24.
   Web of Science ®Google Scholar
• Balasubramanian A, Manzano M, Teramoto T, et al. High-throughput screening for the identification of small-molecule inhibitors of the flaviviral protease. Antiviral Res. 2016;134:6–16.
   PubMed Web of Science ®Google Scholar
• Yao Y, Huo T, Lin YL, et al. Discovery, x-ray crystallography and antiviral activity of allosteric inhibitors of flavivirus NS2B-NS3 protease. J Am Chem Soc. 2019;141(17):6832–6836.
   PubMed Web of Science ®Google Scholar
• Li Z, Sakamuru S, Huang R. et al. Erythrosin B is a potent and broad-spectrum orthosteric inhibitor of the flavivirus NS2B-NS3 protease. Antiviral Res. 2018;150:217–225.
   PubMed Web of Science ®Google Scholar
• Brecher M, Li Z, Liu B. et al. A conformational switch high-throughput screening assay and allosteric inhibition of the flavivirus NS2B-NS3 protease. PLoS Pathog. 2017;13(5):e1006411.
   PubMed Web of Science ®Google Scholar
• Behnam MA, Graf D, Bartenschlager R, et al. Discovery of nanomolar Dengue and West Nile virus protease inhibitors containing a 4-benzyloxyphenylglycine residue. J Med Chem. 2015;58(23):9354–9370.
   PubMed Web of Science ®Google Scholar
• Jia F, Zou G, Fan J, et al. Identification of palmatine as an inhibitor of West Nile virus. Arch Virol. 2010;155(8):1325–1329.
   PubMed Web of Science ®Google Scholar
• Gao Y, Samanta S, Cui T, et al. Synthesis and in vitro evaluation of West Nile virus protease inhibitors based on the 1,3,4,5-tetrasubstituted 1H-pyrrol-2(5H)-one scaffold. ChemMedChem. 2013;8:1554–1560.
   PubMed Web of Science ®Google Scholar
• Li Z, Brecher M, Zhang J, et al. Existing drugs as broad-spectrum and potent inhibitors for Zika virus by targeting NS2B-NS3 interaction. Cell Res. 2017;27:1046–1064.
   PubMed Web of Science ®Google Scholar
• Nitsche C, Passioura T, Varava P, et al. De novo discovery of nonstandard macrocyclic peptides as noncompetitive inhibitors of the Zika virus NS2B-NS3 protease. ACS Med Chem Lett. 2019;10(2):168–174.
   PubMed Web of Science ®Google Scholar
• Martinez AA, Espinosa BA, Adamek RN, et al. Breathing new life into West Nile virus therapeutics; discovery and study of zafirlukast as an NS2B-NS3 protease inhibitor. Eur J Med Chem. 2018;157:1202–1213.
   PubMed Web of Science ®Google Scholar
• Shiryaev SA, Ratnikov BI, Chekanov AV, et al. Cleavage targets and the D-arginine-based inhibitors of the West Nile virus NS3 processing proteinase. Biochem J. 2006;393(Pt 2):503–511.
   PubMedGoogle Scholar
• Stoermer MJ, Chappell KJ, Liebscher S, et al. Potent cationic inhibitors of West Nile virus NS2B/NS3 protease with serum stability, cell permeability and antiviral activity. J Med Chem. 2008;51(18):5714–5721.
   PubMed Web of Science ®Google Scholar
• Schüller A, Yin Z, Brian Chia CS, et al. Tripeptide inhibitors of dengue and West Nile virus NS2B-NS3 protease. Antiviral Res. 2011;92(1):96–101.
   PubMed Web of Science ®Google Scholar
• Lim HA, Joy J, Hill J. San Brian Chia C. Novel agmatine and agmatine-like peptidomimetic inhibitors of the West Nile virus NS2B/NS3 serine protease. Eur J Med Chem. 2011;46(7):3130–3134.
   PubMed Web of Science ®Google Scholar
• Hammamy MZ, Haase C, Hammami M, et al. Development and characterization of new peptidomimetic inhibitors of the West Nile virus NS2B-NS3 protease. ChemMedChem. 2013;8(2):231–241.
   PubMed Web of Science ®Google Scholar
• Pinkham AM, Yu Z, Cowan JA. Attenuation of West Nile virus NS2B/NS3 protease by amino terminal copper and nickel binding (ATCUN) peptides. J Med Chem. 2018;61(3):980–988.
   PubMed Web of Science ®Google Scholar
• Oliveira AFCDS, APM DS, de Oliveira AS, et al. Zirconium catalyzed synthesis of 2-arylidene indan-1,3-diones and evaluation of their inhibitory activity against NS2B-NS3 WNV protease. Eur J Med Chem. 2018;149:98–109.
   PubMed Web of Science ®Google Scholar
• O’Rourke A, Kremb S, Duggan BM, et al. Identification of a 3-alkylpyridinium compound from the red sea sponge Amphimedon chloros with in vitro inhibitory activity against the West Nile virus NS3 protease. Molecules. 2018;23(6):E1472.
   PubMed Web of Science ®Google Scholar
• Kouretova J, Hammamy MZ, Epp A, et al. Effects of NS2B-NS3 protease and furin inhibition on West Nile and dengue virus replication. J Enzyme Inhib Med Chem. 2017;32(1):712–721.
   PubMed Web of Science ®Google Scholar
• Skoreński M, Milewska A, Pyrć K, et al. Phosphonate inhibitors of West Nile virus NS2B/NS3 protease. J Enzyme Inhib Med Chem. 2019;34(1):8–14.
   PubMed Web of Science ®Google Scholar
• Li K, Frankowski KJ, Belon CA, et al. Optimization of potent hepatitis C virus NS3 helicase inhibitors isolated from the yellow dyes thioflavine S and primuline. J Med Chem. 2012;55:3319–3330.
   PubMed Web of Science ®Google Scholar
• Mastrangelo E, Pezzullo M, De Burghgraeve T, et al. Ivermectin is a potent inhibitor of flavivirus replication specifically targeting NS3 helicase activity: new prospects for an old drug. J Antimicrob Chemother. 2012;67:1884–1894.
   PubMed Web of Science ®Google Scholar
• Wang P, Li LF, Wang QY, et al. Anti-dengue-virus activity and structure-activity relationship studies of lycorine derivatives. ChemMedChem. 2014;9(7):1522–1533.
   PubMed Web of Science ®Google Scholar
• Zmurko J, Neyts J, Dallmeier K. Flaviviral NS4B, chameleon and jack-in-the-box roles in viral replication and pathogenesis, and a molecular target for antiviral intervention. Rev Med Virol. 2015;25:205–223.
   PubMed Web of Science ®Google Scholar
• Zou G, Puig-Basagoiti F, Zhang B, et al. A single-amino acid substitution in West Nile virus 2K peptide between NS4A and NS4B confers resistance to lycorine, a flavivirus inhibitor. Virology. 2009;384(1):242–252.
   PubMed Web of Science ®Google Scholar
• Chen H, Liu L, Jones SA, et al. Selective inhibition of the West Nile virus methyltransferase by nucleoside analogs. Antiviral Res. 2013;97(3):232–239.
   PubMed Web of Science ®Google Scholar
• Brecher M, Chen H, Li Z. et al. Identification and characterization of novel broad-spectrum inhibitors of the flavivirus methyltransferase. ACS Infect Dis. 2015;1(8):340–349.
   PubMed Web of Science ®Google Scholar
• Stahla-Beek HJ, April DG, Saeedi BJ. et al. Identification of a novel antiviral inhibitor of the flavivirus guanylyltansferase enzyme. J Virol. 2012;86(16):8730:8739.
   PubMed Web of Science ®Google Scholar
• Bullard KM, Gullberg RC, Soltani E, et al. Murine efficacy and pharmacokinetic evaluation of the flaviviral NS5 capping enzyme 2-thioxothiazolidin-4-one inhibitor BG-323. PLos One. 2015;10(6):e0130083.
   PubMed Web of Science ®Google Scholar
• Jordan I, Briese T, Fischer N, et al. Ribavirin inhibits West Nile virus replication and cytopathic effect in neural cells. J Infect Dis. 2000;182(4):1214–1217.
   PubMed Web of Science ®Google Scholar
• Eyer L, Fojtíková M, Nencka R. et al. Viral RNA-dependent RNA polymerase inhibitor 7-deaza-2ʹ-C-methyladenosine prevents death in a mouse model of West Nile virus infection. Antimicrob Agents Chemother. 2019;63(3):e02093–18.
   PubMed Web of Science ®Google Scholar
• Morrey JD, Taro BS, Siddharthan V. et al. Efficacy of orally administered T-705 pyrazine analog on lethal West Nile virus infection on rodents. Antiviral Res. 2008;80(3):377–379.
   PubMed Web of Science ®Google Scholar
• Eyer L, Zouharová D, Širmarová J, et al. Antiviral activity of the adenosine analogue BCX4430 against West Nile virus and tick-borne flaviviruses. Antiviral Res. 2017;142:63–67.
   PubMed Web of Science ®Google Scholar
• Nelson J, Roe K, Orillo B, et al. Combined treatment of adenosine nucleoside inhibitor NITD008 and histone deacetylase inhibitor vorinostat represents an immunotherapy strategy to ameliorate West Nile virus infection. Antiviral Res. 2015;122:39–45.
   PubMed Web of Science ®Google Scholar
• Cannalire R, Tarantino D, Piorkowski G, et al. Broad spectrum anti-flavivirus pyridobenzothiazolones leading to less infective virions. Antiviral Res. 2019;167:6–12.
   PubMed Web of Science ®Google Scholar
• Tarantino D, Cannalire R, Mastrangelo E, et al. Targeting flavivirus RNA dependent RNA polymerase through a pyridobenzothiazole inhibitor. Antiviral Res. 2016;134:226–235.
   PubMed Web of Science ®Google Scholar
• Furuta Y, Gowen BB, Takahashi K, et al. Favipiravir (T-705), a novel viral RNA polymerase inhibitor. Antiviral Res. 2013;100:446–454.
   PubMed Web of Science ®Google Scholar
• Mentré F, Taburet A-M, Guedj J, et al. Dose regimen of favipiravir for Ebola virus disease. Lancet Infect Dis. 2015;15:150–151.
   PubMed Web of Science ®Google Scholar
• Segura Guerrero NA, Sharma S, Neyts J, et al. Favipiravir inhibits in vitro Usutu virus replication and delays disease progression in an infection model in mice. Antiviral Res. 2018;160:137–142.
   PubMed Web of Science ®Google Scholar
• Abdelnabi R, Morais ATS, Leyssen P, et al. Understanding the mechanism of the broad-spectrum antiviral activity of favipiravir (T-705): key role of the F1 motif of the viral polymerase. J Virol. 2017;91(12):e00487–17.
   PubMed Web of Science ®Google Scholar
• Escribano-Romero E, Jiménez de Oya N, Domingo E. et al. Extinction of West Nile virus by favipiravir through lethal mutagenesis. Antimicrob Agents Chemother. 2017;61(11):e01400–17.
   PubMed Web of Science ®Google Scholar
• Eyer L, Šmídková M, Nencka R, et al. Structure-activity relationships of nucleoside analogues for inhibition of tick-borne encephalitis virus. Antiviral Res. 2016;133:119–129.
   PubMed Web of Science ®Google Scholar
• Eyer L, Nencka R, Huvarová I, et al. Nucleoside inhibitors of Zika virus. J Infect Dis. 2016;214:707–711.
   PubMed Web of Science ®Google Scholar
• Prochnow H, Rox K, Birudukota NVS, et al. Labyrinthopeptins exert broad-spectrum antiviral activity through lipid binding-mediated virolysis. J Virol. 2020;94(2). pii: e01471-19. doi: 10.1128/JVI.01471-19.
   PubMed Web of Science ®Google Scholar
• Boriskin YS, Leneva IA, Pécheur EI, et al. Arbidol: a broad-spectrum antiviral compound that blocks viral fusion. Curr Med Chem. 2008;15(10):997–1005.
   PubMed Web of Science ®Google Scholar
• Pécheur EI, Borisevich V, Halfmann P, et al. The Synthetic antiviral drug arbidol inhibits globally prevalent viruses. J Virol. 2016;90(6):3086–3092.
   PubMed Web of Science ®Google Scholar
• Haviernik J, Štefánik M, Fojtíková M, et al. Arbidol (Umifenovir): A broad-spectrum antiviral drug that inhibits medically important arthropod-borne Flaviviruses. Viruses. 2018;10(4):184.
   PubMed Web of Science ®Google Scholar
• Leneva IA, Russell RJ, Boriskin YS, et al. Characteristics of arbidol-resistant mutants of influenza virus: implications for the mechanism of anti-influenza action of arbidol. Antiviral Res. 2009;81(2):132–140.
   PubMed Web of Science ®Google Scholar
• Kumar P, Wu H, McBride JL, et al. Transvascular delivery of small interfering RNA to the central nervous system. Nature. 2007;448(7149):39–43.
   PubMed Web of Science ®Google Scholar
• Beloor J, Maes N, Ullah I, et al. Small Interfering RNA-mediated control of virus replication in the CNS is therapeutic and enables naturali to West Nile virus. Cell Host Microbe. 2018;23(4):549–556.e3.
   PubMed Web of Science ®Google Scholar
• Krishnan MN, Garcia-Blanco MA. Targeting host factors to treat West Nile and dengue viral infections. Viruses. 2014;6(2):683–708.
   PubMed Web of Science ®Google Scholar
• Shoji-Kawata S, Sumpter R, Leveno M. et al. Identification of a candidate therapeutic autophagy-inducing peptide. Nature. 2013;494(7436):201–206.
   PubMed Web of Science ®Google Scholar
• Medigeshi GR, Kumar R, Dhamija E, et al. N-Desmethylclozapine, Fluoxetine, and Salmeterol inhibit postentry stages of the Dengue virus life cycle. Antimicrob Agents Chemother. 2016;60(11):6709–6718.
   PubMed Web of Science ®Google Scholar
• Pattabhi S, Wilkins CR, Dong R. et al. Targeting innate immunity for antiviral therapy through small molecule agonists of the RLR pathway. J Virol. 2015;90(5):2372–2387.
   PubMed Web of Science ®Google Scholar
• Rausch K, Hackett BA, Weinbren NL, et al. Screening bioactives reveals nanchangmycin as a broad spectrum antiviral active against Zika virus. Cell Rep. 2017;18(3):804–815.
   PubMed Web of Science ®Google Scholar
• Varghese FS, Rausalu K, Hakanen M, et al. Obatoclax inhibits alphavirus membrane fusion by neutralizing the acidic environment of endocytic compartments. Antimicrob Agents Chemother. 2017;61(3):e02227–16.
   PubMed Web of Science ®Google Scholar
• Hackett BA, Dittmar M, Segrist E. et al. Sirtuin inhibitors are broadly antiviral against arboviruses. MBio. 2019;10(4):e01446–19.
   PubMed Web of Science ®Google Scholar
• Medin CL, Fitzgerald KA, Rothman AL. Dengue virus nonstructural protein NS5 induces interleukin-8 transcription and secretion. J Virol. 2005;79:11053–11061.
   PubMed Web of Science ®Google Scholar
• De Maio FA, Risso G, Iglesias NG, et al. The dengue virus NS5 protein intrudes in the cellular spliceosome and modulates splicing. PLoS Pathog. 2016;12:e1005841.
   PubMed Web of Science ®Google Scholar
• Fraser JE, Watanabe S, Wang C, et al. A nuclear transport inhibitor that modulates the unfolded protein response and provides in vivo protection against lethal dengue virus infection. J Infect Dis. 2014;210:1780–1791.
   PubMed Web of Science ®Google Scholar
• Wagstaff KM, Sivakumaran H, Heaton SM, et al. Ivermectin is a specific inhibitor of importin α/β-mediated nuclear import able to inhibit replication of HIV-1 and Dengue virus. Biochem J. 2012;443(3):851–856.
   PubMed Web of Science ®Google Scholar
• Lopez-Denman AJ, Russo A, Wagstaff KM, et al. Nucleocytoplasmic shuttling of the West Nile virus RNA-dependent RNA polymerase NS5 is critical to infection. Cell Microbiol. 2018;20:e12848.
   PubMed Web of Science ®Google Scholar
• Yang SNY, Atkinson SC, Fraser JE. et al. Novel flavivirus antiviral that targets the host nuclear transport importin α/β1 heterodimer. Cells. 2019;8(3):E281.
   PubMed Web of Science ®Google Scholar
• Qing M, Zou G, Wang QY, et al. Characterization of dengue virus resistance to Brequinar in cell Culture. Antimicrob Agents Chemother. 2010;54(9):3686–3695.
   PubMed Web of Science ®Google Scholar
• Luthra P, Naidoo J, Pietzsch CA, et al. Inhibiting pyrimidine biosynthesis impairs Ebola virus replication through depletion of nucleoside pools and activation of innate immune responses. Antiviral Res. 2018;158:288–302.
   PubMed Web of Science ®Google Scholar
• Valiente-Echeverría F, Hermoso MA, Soto-Rifo R. RNA helicase DDX3: at the crossroad of viral replication and antiviral immunity. Rev Med Virol. 2015;25:286−299.
   PubMed Web of Science ®Google Scholar
• Chahar HS, Chen S, Manjunath N. P-body components LSM1, GW182, DDX3, DDX6 and XRN1 are recruited to WNV replication sites and positively regulate viral replication. Virology. 2013;436:1−7.
   PubMed Web of Science ®Google Scholar
• Brai A, Martelli F, Riva V. et al. DDX3X helicase inhibitors as a new strategy to fight the West Nile virus infection. J Med Chem. 2019;62:2333−2347.
   PubMed Web of Science ®Google Scholar
• Brai A, Fazi R, Tintori C, et al. Human DDX3 protein is a valuable target to develop broad spectrum antiviral agents. Proc Natl Acad Sci USA. 2016;113:5388−5393.
   PubMed Web of Science ®Google Scholar
• Blázquez AB, Martín-Acebes MA, Saiz JC. Inhibition of West Nile virus multiplication in cell culture by anti-Parkinsonian drugs. Front Microbiol. 2016;7:296.
   PubMed Web of Science ®Google Scholar
• Blázquez AB, Vázquez-Calvo Á, Martín-Acebes MA, et al. Pharmacological inhibition of protein kinase C reduces West Nile virus replication. Viruses. 2018;10(2):E91.
   PubMed Web of Science ®Google Scholar
• Marceau CD, Puschnik AS, Majzoub K, et al. Genetic dissection of Flaviviridae host factors through genome-scale CRISPR screens. Nature. 2016;535(7610):159–163.
   PubMed Web of Science ®Google Scholar
• Richardson RB, Ohlson MB, Eitson JL, et al. A CRISPR screen identifies IFI6 as an ER-resident interferon effector that blocks flavivirus replication. Nat Microbiol. 2018;3(11):1214–1223.
   PubMed Web of Science ®Google Scholar
• Puschnik AS, Marceau CD, Ooi YS, et al. A small-molecule oligosaccharyltransferase inhibitor with pan-flaviviral activity. Cell Rep. 2017;21(11):3032–3039.
   PubMed Web of Science ®Google Scholar
• Chang J, Wang L, Ma D. et al. Novel imino sugar derivatives demonstrate potent antiviral activity against Flaviviruses. Antimicrob Agents Chemother. 2009;53(4):1501–1508.
   PubMed Web of Science ®Google Scholar
• Sayce AC, Alonzi DS, Killingbeck SS, et al. Iminosugars inhibit Dengue virus production via inhibition of ER alpha-glucosidases–not glycolipid processing enzymes. PLoS Negl Trop Dis. 2016;10(3):e0004524.
   PubMed Web of Science ®Google Scholar
• Rathore AP, Paradkar PN, Watanabe S, et al. Celgosivir treatment misfolds dengue virus NS1 protein, induces cellular pro-survival genes and protects against lethal challenge mouse model. Antiviral Res. 2011;92(3):453–460.
   PubMed Web of Science ®Google Scholar
• Watanabe S, Chan KW, Dow G, et al. Optimizing celgosivir therapy in mouse models of dengue virus infection of serotypes 1 and 2: the search for a window for potential therapeutic efficacy. Antiviral Res. 2016;127:10–19.
   PubMed Web of Science ®Google Scholar
• Watanabe S, Rathore AP, Sung C, et al. Dose- and schedule-dependent protective efficacy of celgosivir in a lethal mouse model for dengue virus infection informs dosing regimen for a proof of concept clinical trial. Antiviral Res. 2012;96(1):32–35.
   PubMed Web of Science ®Google Scholar
• Low JG, Sung C, Wijaya L, et al. Efficacy and safety of celgosivir in patients with dengue fever (CELADEN): a phase 1b, randomised, double-blind, placebo-controlled, proof-of-concept trial. Lancet Infect Dis. 2014;14(8):706–715.
   PubMed Web of Science ®Google Scholar
• Ivanova T, Hardes K, Kallis S, et al. Optimization of substrate-analogue furin inhibitors. ChemMedChem. 2017;12(23):1953–1968.
   PubMed Web of Science ®Google Scholar
• Backus KM, Correia BE, Lum KM, et al. Proteome-wide covalent ligand discovery in native biological systems. Nature. 2016;534(7608):570–574.
   PubMed Web of Science ®Google Scholar
• de Wispelaere M, Carocci M, Liang Y, et al. Discovery of host-targeted covalent inhibitors of dengue virus. Antiviral Res. 2017;139:171–179.
   PubMed Web of Science ®Google Scholar
• Merino-Ramos T, Jiménez de Oya N, Saiz JC, et al. Antiviral activity of nordihydroguaiaretic acid and its derivative tetra-o-methyl nordihydroguaiaretic acid against West Nile virus and Zika virus. Antimicrob Agents Chemother. 2017;61(8):e00376–17.
   PubMed Web of Science ®Google Scholar
• Jiménez de Oya N, Esler WP, Huard K. et al. Targeting host metabolism by inhibition of acetyl- coenzyme a carboxylase reduces flavivirus infection in mouse models. Emerg Microbes Infect. 2019;8(1):624–636.
   PubMed Web of Science ®Google Scholar
• Soto-Acosta R, Bautista-Carbajal P, Syed GH, et al. Nordihydroguaiaretic acid (NDGA) inhibits replication and viral morphogenesis of dengue virus. Antiviral Res. 2014;109:132–140.
   PubMed Web of Science ®Google Scholar
• Merino-Ramos T, Vázquez-Calvo Á, Casas J, et al. Modification of the host cell lipid metabolism induced by hypolipidemic drugs targeting the acetyl coenzyme A carboxylase impairs West Nile virus replication. Antimicrob Agents Chemother. 2015;60(1):307–315.
   PubMed Web of Science ®Google Scholar
• Wichit S, Hamel R, Bernard E, et al. Imipramine inhibits Chikungunya virus replication in human skin fibroblasts through interference with intracellular cholesterol trafficking. Sci Rep. 2017;7(1):3145.
   PubMedGoogle Scholar
• Cheng F, Ramos da Silva S, Huang IC, et al. Suppression of Zika virus infection and replication in endothelial cells and astrocytes by PKA inhibitor PKI 14-22. J Virol. 2018;92(4):e02019–17.
   PubMed Web of Science ®Google Scholar
• Soto-Acosta R, Bautista-Carbajal P, Cervantes-Salazar M, et al. DENV up-regulates the HMG-CoA reductase activity through the impairment of AMPK phosphorylation: A potential antiviral target. PLoS Pathog. 2017;13(4):e1006257.
   PubMed Web of Science ®Google Scholar
• Jiménez de Oya N, Blázquez AB, Casas J, et al. Direct activation of adenosine monophosphate-activated protein kinase (AMPK) by PF-06409577 inhibits flavivirus infection through modification of host cell lipid metabolism. Antimicrob Agents Chemother. 2018;62(7):e00360–18.
   PubMed Web of Science ®Google Scholar
• Barzon L, Pacenti M, Ulbert S, et al. Latest developments and challenges in the diagnosis of human West Nile virus infection. Expert Rev Anti Infect Ther. 2015 Mar;13(3):32.
   Web of Science ®Google Scholar